Exelixis, Inc. (EXEL) shareholders
Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 28,499,470 | 10.20% | 13G (passive) amendment | Mar 31, 2025 |
| Seybold, William Joint filing with Wehrly, Mark C. (8.40%), Short Daniel S. (8.40%) and 17 more | 23,439,500 | 8.40% | 13D (active) amendment | Mar 5, 2025 |
| Gehani, Varun N. Joint filing with Wehrly, Mark C. (5.90%), Dapice Joshua J. (5.90%) and 13 more | 15,709,500 | 5.90% | 13D (active) amendment | Jan 1, 2026 |
| Renaissance Technologies Holdings Corporation Joint filing with Renaissance Technologies LLC (5.16%) | 15,615,716 | 5.16% | 13G (passive) | Dec 19, 2023 |
| Kim, David T. Joint filing with Farallon Capital Management, L.L.C. (6.00%), Dapice Joshua J. (6.00%) and 13 more | 14,694,910 | 6.00% | 13G (passive) | Nov 9, 2026 |
| Wehrly, Mark C. Joint filing with Farallon Capital Management, L.L.C. (5.60%), Dapice Joshua J. (5.60%) and 13 more | 13,989,010 | 5.60% | 13D (active) amendment | Aug 14, 2026 |
| AQR Capital Management Holdings, LLC Joint filing with AQR Capital Management, LLC (5.09%) | 13,658,388 | 5.09% | 13G (passive) | Dec 31, 2025 |
| Vanguard Capital Management | 13,233,247 | 5.09% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EXEL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 29,075,377 | 11.92% | $1.58B | −1,740,932 | 0.02% |
| Farallon Capital Management LLC | 13,468,010 | 5.52% | $732.79M | +357,000 | 3.38% |
| Renaissance Technologies LLC | 13,427,993 | 5.50% | $730.62M | −299,000 | 1.01% |
| Vanguard Portfolio Management LLC | 12,043,122 | 4.94% | $655.27M | −42,151 | 0.03% |
| Aqr Capital Management LLC | 11,023,943 | 4.52% | $598.60M | −2,071,798 | 0.21% |
| Vanguard Capital Management LLC | 10,950,997 | 4.49% | $595.84M | −307,987 | 0.01% |
| State Street Corp | 9,970,071 | 4.09% | $542.47M | −328,368 | 0.02% |
| Fuller & Thaler Asset Management, Inc. | 8,929,389 | 3.66% | $485.85M | +387,153 | 1.32% |
| Lsv Asset Management | 8,146,478 | 3.34% | $443.25M | +400,763 | 0.80% |
| Geode Capital Management, LLC | 7,650,316 | 3.14% | $416.32M | −145,294 | 0.02% |
| D. E. Shaw & Co., Inc. | 5,551,747 | 2.28% | $302.07M | +1,948,684 | 0.14% |
| Morgan Stanley | 4,519,684 | 1.85% | $245.92M | +341,448 | 0.01% |
| Invesco Ltd. | 4,495,697 | 1.84% | $244.61M | +181,316 | 0.02% |
| Dimensional Fund Advisors LP | 4,426,620 | 1.81% | $240.85M | +127,023 | 0.04% |
| Arrowstreet Capital, Limited Partnership | 4,365,926 | 1.79% | $237.55M | −468,699 | 0.11% |
| Two Sigma Investments, LP | 4,209,861 | 1.73% | $229.06M | +2,003,649 | 0.17% |
| Assetmark, Inc | 3,433,824 | 1.41% | $186.83M | +44,904 | 0.32% |
| Nuveen, LLC | 3,276,984 | 1.34% | $178.30M | −505,750 | 0.04% |
| UBS Group AG | 3,167,890 | 1.30% | $172.36M | +774,377 | 0.02% |
| Stephens Investment Management Group LLC | 2,710,011 | 1.11% | $147.45M | +185,511 | 1.58% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 756 | 260M | 100.0% | 131 / 257 | 282 / 64 | 23M | 21M |
| Q1 2026 | 701 | 259M | 100.0% | 104 / 246 | 266 / 78 | 46M | 29M |
| Q4 2025 | 685 | 268M | 100.0% | 132 / 234 | 241 / 59 | 36M | 19M |
| Q3 2025 | 621 | 252M | 100.0% | 82 / 224 | 239 / 89 | 24M | 29M |
| Q2 2025 | 635 | 257M | 100.0% | 125 / 234 | 215 / 42 | 28M | 25M |
| Q1 2025 | 558 | 254M | 100.0% | 100 / 216 | 173 / 55 | 27M | 19M |
| Q4 2024 | 519 | 251M | 100.0% | 117 / 175 | 167 / 45 | 25M | 25M |
| Q3 2024 | 454 | 253M | 100.0% | 82 / 144 | 162 / 41 | 54M | 16M |
| Q2 2024 | 416 | 249M | 100.0% | 42 / 142 | 173 / 43 | 12M | 32M |
| Q1 2024 | 422 | 269M | 100.0% | 55 / 136 | 166 / 59 | 21M | 24M |
| Q4 2023 | 427 | 272M | 100.0% | 74 / 137 | 156 / 39 | 29M | 21M |
| Q3 2023 | 399 | 264M | 100.0% | 52 / 134 | 151 / 28 | 18M | 25M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
603 funds held EXEL in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of EXEL | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 8,601,933 | 3.53% | $468.03M | 0.38% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 7,583,078 | 3.11% | $412.60M | 0.02% | Jun 30, 2026 |
| Fullerthaler Behavioral Small Cap Equity | 7,041,516 | 2.89% | $383.13M | 3.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 5,473,447 | 2.24% | $297.81M | 0.16% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 3,156,071 | 1.29% | $171.72M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,881,831 | 1.18% | $156.80M | 0.16% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF | 2,773,550 | 1.14% | $147.08M | 2.70% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,893,798 | 0.78% | $103.04M | 0.96% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,726,035 | 0.71% | $93.91M | 1.03% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,714,400 | 0.70% | $93.28M | 3.32% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,506,131 | 0.62% | $79.87M | 0.36% | Jul 31, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 1,503,757 | 0.62% | $81.82M | 0.72% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,336,929 | 0.55% | $67.49M | 0.16% | May 31, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 1,274,068 | 0.52% | $64.31M | 0.06% | May 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF | 1,272,309 | 0.52% | $69.23M | 0.38% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Morrissey | President and CEO, Director | 3,384,063 | 1.39% | May 19, 2026 |
| Dana Aftab | EVP, Research and Development | 600,576 | 0.25% | May 28, 2026 |
| Patrick J. Haley | EVP, Commercial | 357,638 | 0.15% | May 22, 2026 |
| Brenda Hefti | SVP and General Counsel | 112,289 | 0.05% | May 19, 2026 |
| Christopher J. Senner | EVP and CFO | 955,040 | 0.39% | May 19, 2026 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 538,169 | 0.22% | May 16, 2025 |
| Jeffrey Hessekiel | EVP & General Counsel | 694,395 | 0.28% | May 16, 2025 |
| Mary C. Beckerle | Director | 16,079 | 0.01% | Aug 12, 2026 |
| Sue Gail Eckhardt | Director | 16,079 | 0.01% | Jun 3, 2026 |
| Jack L. Wyszomierski | Director | 284,384 | 0.12% | Jun 3, 2026 |
| Julie Smith | Director | 28,957 | 0.01% | May 29, 2026 |
| George Poste | Director | 127,199 | 0.05% | May 29, 2026 |
| Stelios Papadopoulos | Director | 1,197,595 | 0.49% | May 29, 2026 |
| Maria C. Freire | Director | 109,186 | 0.04% | May 29, 2026 |
| Tomas J. Heyman | Director | 50,649 | 0.02% | May 29, 2026 |
| David Edward Johnson | Director | 1,543,906 | 0.63% | May 29, 2026 |
| Partners LP Caligan | Director | 1,571,438 | 0.64% | May 29, 2026 |
| Bob Oliver | Director | 29,487 | 0.01% | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mary C. Beckerle Director | Aug 10, 2026 | Sale(10b5-1 plan) | −9,812 | $53.66 | $526.51K | 16,079 |
| Jack L. Wyszomierski Director | Jun 1, 2026 | Sale(10b5-1 plan) | −3,925 | $50.55 | $198.41K | 284,384 |
| Sue Gail Eckhardt Director | Jun 1, 2026 | Sale(10b5-1 plan) | −9,812 | $50.14 | $491.97K | 16,079 |
| Mary C. Beckerle Director | May 27, 2026 | Award | +8,367 | – | – | 25,891 |
| George Poste Director | May 27, 2026 | Award | +8,367 | – | – | 127,199 |
| Bob Oliver Director | May 27, 2026 | Award | +8,367 | – | – | 29,487 |
| Stelios Papadopoulos Director | May 27, 2026 | Award | +8,367 | – | – | 1,197,595 |
| Julie Smith Director | May 27, 2026 | Award | +8,367 | – | – | 28,957 |
| Tomas J. Heyman Director | May 27, 2026 | Award | +8,367 | – | – | 50,649 |
| Maria C. Freire Director | May 27, 2026 | Award | +8,367 | – | – | 109,186 |
| Jack L. Wyszomierski Director | May 27, 2026 | Award | +8,367 | – | – | 288,309 |
| Sue Gail Eckhardt Director | May 27, 2026 | Award | +8,367 | – | – | 25,891 |
| Dana Aftab EVP, Research and Development | May 26, 2026 | Sale | −43,451 | $50.35 | $2.19M | 594,741 |
| Patrick J. Haley EVP, Commercial | May 20, 2026 | Sale | −32,110 | $49.81 | $1.60M | 357,638 |
| Michael Morrissey President and CEO, Director | May 18, 2026 | Gift | +124,047 | – | – | 2,004,327 |
| Michael Morrissey President and CEO, Director | May 18, 2026 | Gift | −124,047 | – | – | 1,362,008 |
| Brenda Hefti SVP and General Counsel | May 18, 2026 | Sale(10b5-1 plan) | −6,625 | $50.21 | $332.64K | 106,762 |
| Christopher J. Senner EVP and CFO | May 18, 2026 | Sale | −34,901 | $50.00 | $1.75M | 952,317 |
| Michael Morrissey President and CEO, Director | May 15, 2026 | Tax withholding | −128,497 | $51.10 | $6.57M | 1,486,055 |
| Patrick J. Haley EVP, Commercial | May 15, 2026 | Tax withholding | −33,265 | $51.10 | $1.70M | 389,748 |
| Dana Aftab EVP, Research and Development | May 15, 2026 | Tax withholding | −30,578 | $51.10 | $1.56M | 638,192 |
| Brenda Hefti SVP and General Counsel | May 15, 2026 | Tax withholding | −6,411 | $51.10 | $327.60K | 113,387 |
| Christopher J. Senner EVP and CFO | May 15, 2026 | Tax withholding | −40,892 | $51.10 | $2.09M | 987,218 |
| George Poste Director | May 7, 2026 | Sale | −60,000 | $45.71 | $2.74M | 118,832 |
| Maria C. Freire Director | May 7, 2026 | Option exercise | +20,634 | $19.77 | $407.93K | 121,453 |
| Maria C. Freire Director | May 7, 2026 | Sale | −20,634 | $46.00 | $949.16K | 100,819 |
| Mary C. Beckerle Director | May 7, 2026 | Option exercise | +3,856 | $23.24 | $89.61K | 25,236 |
| Mary C. Beckerle Director | May 7, 2026 | Sale | −7,712 | $48.45 | $373.65K | 17,524 |
| Michael Morrissey President and CEO, Director | May 6, 2026 | Gift | −109,676 | – | – | 1,880,280 |
| Christopher J. Senner EVP and CFO | Feb 26, 2026 | Award | +52,018 | – | – | 1,028,110 |
| Patrick J. Haley EVP, Commercial | Feb 26, 2026 | Award | +40,459 | – | – | 422,367 |
| Dana Aftab EVP, Research and Development | Feb 26, 2026 | Award | +52,018 | – | – | 668,124 |
| Michael Morrissey President and CEO, Director | Feb 26, 2026 | Award | +160,437 | – | – | 1,614,552 |
| Brenda Hefti SVP and General Counsel | Feb 26, 2026 | Award | +23,119 | – | – | 119,631 |
| Michael Morrissey President and CEO, Director | Feb 24, 2026 | Gift | −100,278 | – | – | 1,989,956 |
| Dana Aftab EVP, Research and Development | Feb 24, 2026 | Sale | −47,918 | $44.50 | $2.13M | 616,106 |
| Dana Aftab EVP, Research and Development | Feb 19, 2026 | Sale | −29,873 | $44.35 | $1.32M | 664,024 |
| Jack L. Wyszomierski Director | Feb 18, 2026 | Sale(10b5-1 plan) | −99,574 | $44.01 | $4.38M | 279,942 |
| Jack L. Wyszomierski Director | Feb 18, 2026 | Option exercise | +20,634 | $19.77 | $407.93K | 379,516 |
| Julie Smith Director | Feb 18, 2026 | Sale | −20,030 | $44.30 | $887.33K | 20,590 |
| Julie Smith Director | Feb 18, 2026 | Option exercise | +44,087 | $19.39 | $854.85K | 64,677 |
| Julie Smith Director | Feb 18, 2026 | Sale | −44,087 | $44.50 | $1.96M | 20,590 |
| Julie Smith Director | Feb 18, 2026 | Option exercise | +20,030 | $21.69 | $434.45K | 40,620 |
| Brenda Hefti SVP and General Counsel | Feb 18, 2026 | Sale(10b5-1 plan) | −18,669 | $44.01 | $821.62K | 96,512 |
| Michael Morrissey President and CEO, Director | Feb 18, 2026 | Gift | +125,094 | – | – | 2,090,234 |
| Michael Morrissey President and CEO, Director | Feb 18, 2026 | Gift | −125,094 | – | – | 1,454,115 |
| Julie Smith Director | Feb 17, 2026 | Option exercise | +42,422 | $18.19 | $771.66K | 63,012 |
| Julie Smith Director | Feb 17, 2026 | Sale | −42,422 | $43.33 | $1.84M | 20,590 |
| Michael Morrissey President and CEO, Director | Feb 17, 2026 | Gift | +250,736 | – | – | 1,965,140 |
| Michael Morrissey President and CEO, Director | Feb 17, 2026 | Gift | −250,736 | – | – | 1,579,209 |
| Patrick J. Haley EVP, Commercial | Feb 17, 2026 | Sale | −64,778 | $43.50 | $2.82M | 381,908 |
| Patrick J. Haley EVP, Commercial | Feb 17, 2026 | Sale | −3,036 | $43.84 | $133.10K | 446,686 |
| Christopher J. Senner EVP and CFO | Feb 17, 2026 | Sale | −30,617 | $43.67 | $1.34M | 976,092 |
| Brenda Hefti SVP and General Counsel | Feb 15, 2026 | Tax withholding | −5,430 | $43.92 | $238.49K | 115,181 |
| Dana Aftab EVP, Research and Development | Feb 15, 2026 | Tax withholding | −26,485 | $43.92 | $1.16M | 706,617 |
| Dana Aftab EVP, Research and Development | Feb 15, 2026 | Tax withholding | −12,720 | $43.92 | $558.66K | 693,897 |
| Michael Morrissey President and CEO, Director | Feb 15, 2026 | Tax withholding | −120,390 | $43.92 | $5.29M | 1,829,945 |
| Patrick J. Haley EVP, Commercial | Feb 15, 2026 | Tax withholding | −31,483 | $43.92 | $1.38M | 449,722 |
| Christopher J. Senner EVP and CFO | Feb 15, 2026 | Tax withholding | −35,870 | $43.92 | $1.58M | 1,006,709 |
| Michael Morrissey President and CEO, Director | Feb 13, 2026 | Option exercise | +494,700 | $21.31 | $10.54M | 2,319,941 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Exelixis's stock actually held short. Settlement fails (shares not delivered on time) peaked at 600 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mary C. Beckerle Director | Aug 10, 2026 | 9,812 | $526.50K | Aug 10, 2026 | Restricted Stock |
| Sue Gail Eckhardt Director | Jun 1, 2026 | 9,812 | $499.14K | Jun 1, 2026 | Restricted Stock Unit |
| Jack L. Wyszomierski Director | Jun 1, 2026 | 3,925 | $198.41K | Jun 1, 2026 | Restricted Stock |
| Dana Aftab Officer | May 26, 2026 | 43,451 | $2.19M | May 26, 2026 | Restricted stock vesting under a registered plan |
| Patrick J. Haley Officer | May 20, 2026 | 32,110 | $1.60M | May 20, 2026 | Restricted stock vesting under a registered plan |
| Brenda Hefti Officer | May 18, 2026 | 6,625 | $332.64K | May 18, 2026 | Restricted Stock |
| Christopher J. Senner Officer | May 18, 2026 | 34,901 | $1.75M | May 18, 2026 | Restricted stock vesting under a registered plan |
| Bombora Rise Foundation Family foundation of the CEO of EXEL. | May 14, 2026 | 100,000 | $5.09M | May 14, 2026 | Gift from Affiliate |
| Maria C. Freire Director | May 7, 2026 | 20,634 | $949.16K | May 7, 2026 | Exercise of options under a registered plan |
| George Poste Director | May 7, 2026 | 60,000 | $2.74M | May 7, 2026 | Restricted stock vesting under a registered plan |
| Mary C. Beckerle Director | May 7, 2026 | 7,712 | $373.65K | May 7, 2026 | Restricted stock vesting under a registered plan |
| Dana Aftab Officer | Feb 24, 2026 | 47,918 | $2.13M | Feb 24, 2026 | Performance Shares |
| Dana Aftab Officer | Feb 19, 2026 | 29,873 | $1.32M | Feb 19, 2026 | Performance Shares |
| Jack L. Wyszomierski Director | Feb 18, 2026 | 99,574 | $4.38M | Feb 18, 2026 | Exercised Shares |
| Brenda Hefti Officer | Feb 18, 2026 | 18,669 | $821.66K | Feb 18, 2026 | Performance Shares |
Congress trades
4 trades in Exelixis reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Donna Shalala FL27 | Sold | Jun 4, 2019 | $1K–15K | Apr 27, 2020 328 days late |
| Donna Shalala FL27 | Sold (part) | Apr 16, 2019 | $1K–15K | Apr 27, 2020 377 days late |
| Donna Shalala FL27 | Bought | Feb 6, 2019 | $1K–15K | Apr 27, 2020 446 days late |
| Donna Shalala FL27 | Bought | Jan 9, 2019 | $1K–15K | Apr 27, 2020 474 days late |
See a number that looks wrong?